Steroid-sensitive recurrent mesangial proliferative glomerulonephritis with monoclonal IgG deposits.
Nomura K, Miyatake N, Okada K, Hayashi N, Fujimoto K, Adachi H, Furuichi K, Shimizu A, Yokoyama H.
CEN Case Rep. 2021 May;10(2):308-313. doi: 10.1007/s13730-020-00562-x. Epub 2021 Jan 4.
PMID:33398782
Expression and clinical significance of thrombospondin-1 and plasminogen activator inhibitor-1 in patients with mesangial proliferative glomerulonephritis.
Pan C, Zhou C, Shan A, Chen N.
Ann Palliat Med. 2020 Sep;9(5):3187-3193. doi: 10.21037/apm-20-1291. Epub 2020 Aug 31.
PMID:32921106
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
Ohtake T, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Kobayashi S.
Promising response of proliferative glomerulonephritis with monoclonal IgG deposits to low-dose daratumumab: a case report.
Xu H, Huang Y, Dong L, Yu H, Lin B.
Front Med (Lausanne). 2024 Jul 24;11:1360979. doi: 10.3389/fmed.2024.1360979. eCollection 2024.
PMID:39114824
Steroid-responsive nephrotic syndrome in a patient with proliferative glomerulonephritis with monoclonal IgG deposits with pure mesangial proliferative features.
Komatsuda A, Wakui H, Ohtani H, Nimura T, Sawada K.
NDT Plus. 2010 Aug;3(4):357-9. doi: 10.1093/ndtplus/sfq076. Epub 2010 May 2.